Technical Analysis for AMAM - Ambrx Biopharma Inc.

Grade Last Price % Change Price Change
A 28.00 0.07% 0.02
AMAM closed up 0.07 percent on Wednesday, March 6, 2024, on 72 percent of normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.
3 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Very Strong Up Up Flat

Date Alert Name Type % Chg
New Downtrend Bearish 105.43%
Bullish Engulfing Bullish 105.43%
Pocket Pivot Bullish Swing Setup 105.43%
20 DMA Resistance Bearish 109.58%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 109.58%
Inside Day Range Contraction 109.58%
20 DMA Resistance Bearish 106.03%
Doji - Bullish? Reversal 106.03%
Fell Below 20 DMA Bearish 106.79%
Down 3 Days in a Row Weakness 106.79%

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Ambrx is a clinical stage biopharmaceutical company using an expanded genetic code technology platform to discover and develop Engineered Precision Biologics. These include next generation antibody drug conjugates (ADCs), bispecifics, targeted immuno-oncology therapies, novel cytokines to modulate the immune system, and long-acting therapeutic peptides for metabolic and cardiovascular disease. Ambrx is advancing a robust portfolio of clinical and preclinical programs designed to optimize efficacy, safety and ease of use, in multiple therapeutic areas, including its lead product candidate ARX788. In addition, the company has clinical collaborations with Bristol Myers Squibb, Astellas, BeiGene, Sino Biopharma, Elanco and NovoCodex, for drug candidates generated using Ambrx technology.
Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Life Sciences Immunology Health Sciences Pharmacy Cancer Immunotherapy Antibody Drug Conjugate Oncology Therapies Beigene

Is AMAM a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 28.15
52 Week Low 6.56
Average Volume 1,997,117
200-Day Moving Average 15.99
50-Day Moving Average 25.33
20-Day Moving Average 27.86
10-Day Moving Average 27.95
Average True Range 0.18
RSI (14) 82.17
ADX 55.72
+DI 43.61
-DI 13.57
Chandelier Exit (Long, 3 ATRs) 27.48
Chandelier Exit (Short, 3 ATRs) 28.06
Upper Bollinger Bands 28.05
Lower Bollinger Band 27.66
Percent B (%b) 0.86
BandWidth 1.40
MACD Line 0.66
MACD Signal Line 0.90
MACD Histogram -0.2404
Fundamentals Value
Market Cap 1.77 Billion
Num Shares 63.3 Million
EPS 0.42
Price-to-Earnings (P/E) Ratio 66.67
Price-to-Sales 429.71
Price-to-Book 7.26
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 28.03
Resistance 3 (R3) 28.03 28.01 28.03
Resistance 2 (R2) 28.01 28.01 28.02 28.02
Resistance 1 (R1) 28.01 28.00 28.01 28.01 28.02
Pivot Point 27.99 27.99 28.00 28.00 27.99
Support 1 (S1) 27.99 27.99 27.99 27.99 27.98
Support 2 (S2) 27.97 27.98 27.98 27.98
Support 3 (S3) 27.97 27.97 27.98
Support 4 (S4) 27.97